Novartis files reply in support of dismissing Regeneron's claims over eye treatment
MLex Summary: Novartis filed a reply brief supporting its motion to dismiss Regeneron Pharmaceuticals’ antitrust claims over eye treatments delivered through pre-filled syringes, saying Regeneron’s defense is merely a smokescreen. It...To view the full article, register now.
Already a subscriber? Click here to view full article